Small molecule · Inhibitor of TGF-beta receptor type 1 (TGFBR1) · developed by ELI LILLY &
Galunisertib is an orally available small molecule that binds the kinase domain of the TGF-beta receptor type 1 (TGFBR1), preventing activation of TGF-beta-mediated signaling. It is studied in prostate cancer.
Summary written with AI from the sources listed at the end of this page.
Prostate Cancer
Updated Nov 8, 2026. Something wrong or missing? Report it on the LLY page.
See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LLY catalysts and pipeline →